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Drug-induced heterogeneity of cancer cells is a known concept that is not well understood. 
Heterogeneity is a common characteristic of cancer and describes how cancer cells of the 
same tumour can show distinct morphologies and genetic phenotypes, due to an increased 
cell cycle and thus elevated occurrence of mutations. The exposure of cancer to drugs is 
thought to be a diver of heterogeneity leading to acquired-drug resistance. This is when a 
cancer mass that was once sensitive to a particular drug is no longer effected by it and results 
in treatment failure, leading to loss of life of the patient if no other treatments are available. 
The problem with heterogeneity and acquired-ĚƌƵŐƌĞƐŝƐƚĂŶĐĞŝƐƚŚĞǇĐĂŶ ?ƚďĞĞĂƐŝůǇƐƚƵĚŝĞĚ 
due to the need for multiple and extensive biopsies of the ƉĂƚŝĞŶƚ ?Ɛ cancer. Therefore the 
only way to study the process of the formation of drug-induced heterogeneity is through 
experimental investigations into model cell lines.  
Here we attempt to standardise an adaptation protocol for the formation of resistant cell 
lines, with the aim of creating a protocol that allows comparison between different cell lines 
and different drugs. We also wish to better understand the formation of resistance in UKF-
NB-3 cell lines with the hope of later identifying cross-resistance with other drugs. Moreover, 
we aim the better understand heterogeneity by establishing clonal cell lines of UKF-NB-3 
and exposing them to a number of tubulin-binding drugs, with the aim of making 
comparisons between the clones and other established clones with acquired resistance to a 
number of drugs.  
We found that repeated adaptation of cell lines to the same drug results in resistant 
heterogenic sub-lines. We also concluded that exposure of cells to drugs of a similar 








Neuroblastoma is a childhood cancer that is often diagnosed in the first year of life and  
accounts for 15% of paediatric oncology deaths in children aged between 0 to 14 years old 
(Ries et al. 2007) .   Patients with a high-risk phenotype have a long-term survival rate of less 
than 40% (Maris et al, 2007).  Like with most cancers, a high risk phenotype is defined by the 
spread of the cancer to other parts of the body, and for neuroblastoma, around 60% of cases 
result in a metastatic disease state (Cheung & Dyer, 2013). Neuroblastoma is an embryonal 
tumour from cells of sympathoadrenal linage of the neural crest (Anderson et al, 1991). This 
is only present during embryogenesis, suggestive of why the cancer is mainly found amongst 
young children, resulting in tumour development within the sympathetic nervous system, 
primarily (65%) within the abdomen but also identified in the neck, chest and pelvis regions 
(Cheung & Dyer, 2013; Maris et al, 2007). 
There are two types of Neuroblastoma; Familial or Sporadic. Familial neuroblastoma is rare 
and linked to a hereditary cause (Maris et al 2002). It is characterized by mutations in the 
paired-like homeobox 2b (PHOX2B) which encodes transcription factors that promote cell 
cycle exit and neural differentiation (Mosse et al. 2004). Other mutations also include those 
found in the anaplastic lymphoma receptor tyrosine kinase (ALK) gene which regulates 
proliferation and differentiation (Cheung & Dyer, 2013). Sporadic neuroblastoma is 
commonly associated with the amplification of the MYCN gene, occuring in 22% of tumours 
and often results in a negative outcome for the patient (Brodeur, 2003). 
Metastises often develop in cortical bone, bone marrow, liver and lymph nodes (Quinn, 




cancer.  There is often a poor outcome for those whos cancer has reached stage 4 i.e. when 
the cancer begins to metastasise. However this is not the case for those whos cancer is in 
the rare and special 4S disease stage. This is a unique occurance, found in 5% of cases,  where 
the matastesises that have disseminated to the afore mentioned organs, spontaneously 
regress (D'Angio et al, 1971). These patients then fall into a low-risk category with a survival 
rate between 85-90% unless MYCN amplifications are observed (Nickerson et al 2000).  
Though there is a low survival rate for patients with a high risk phenotype, greater than 50% 
of these paitents would have originally responeded well to selective multi-modal therapies. 
This relapes is often attributed to the development acquired drug resistance or clonal 
evolution (the expantion of risistant cells within a heterogeneous tumor environment).  
II) Microtubules 
 
Microtubules make up part of cytoskeleton, a system of filaments involved in the 
organisation and stability of the cell. Microtubules play a specific role in cell division and 
make up cells mitotic spindles.  
They are typically comprised of 13 protofilaments that form a hollow tube approximately 
 ? ?ŶŵŝŶĚŝĂŵĞƚĞƌ ?WƌŽƚŽĨŝůĂŵĞŶƚƐĐŽŶƐŝƐƚŽĨĂŚĞƚĞƌŽĚŝŵĞƌŽĨɲ- ĂŶĚɴ-tubulin molecules 
ƚŚĂƚǁŚĞŶďŽƵŶĚƚŽ'WƚŚƌŽƵŐŚĂŶĂĐƚŝǀĞƐŝƚĞŽŶƚŚĞɴ-tubulin, causes a bent confirmation 
that prevents their incorporation into a microtubule (Howard et al, 2007). However, 
exchange of GDP for GTP allows the dimer to become incorporated into the microtubule 
and thus GTP-tubulin is often thought of as the fuel for polymerization. The hydrolysis of 
GTP, on the other hand, permits disassembly of the dimer (Abal, 2003). 
Microtubules have two districted ends, one (referred to as the minus-end) is anchored to 




polymerisation and depolymerisation (Etienne-Manneville, 2010). The regulation of 
microtubule growth is dictated by the interactions with a family of proteins known as 
microtubule associated proteins (MAPs). They also control the number of microtubules 
present during mitosis.  
III) Tubulin binding agents 
 
Tubulin binding agents (TBA) interfere with the dynamics of microtubules during mitosis. 
They aim to cause cell cycle arrest leading to the prevention of cellular proliferation and in 
some cases, trigger apoptosis of the cell. TBAs consist of a wide range of drugs, both natural 
and synthetic, that can be separated depending on their mode of action, as TBAs can both 
stabilise microtubules preventing their depolymerisation or destabilise them, encouraging 
depolymerisation and preventing further growth of the tubule (Kavallaris, 2010).  Examples 
of different drugs can be seen below in Table 1.  
Destabilising agents Stabilising agents 
Vina binding site Colchicine binding site Taxane binding site 
Vincristine Combretastatin A4 Docetaxel 
Vinblastine 2-Methoxyestradiol Epithilone B  
  Paclitaxel 
 
^ƚĂďŝůŝƐŝŶŐĂŐĞŶƚƐďŝŶĚƚŽƚŚĞƚĂǆĂŶĞƉŽĐŬĞƚŽĨɴ-tubulin molecules within the microtubule  
(depicted in figure 1). It has been shown that the binding of stabilising agents causes a 
conformational change within the corresponding tubulin molecule (specifically causing a 
short-helix at the M-ůŽŽƉ ǁŝƚŚŝŶ ƚŚĞ ɴ-tubulin molecule) that allows for lateral tubulin 
interactions within the microtubule, thereby stabilizing the molecule and preventing its 




depolymerisation (Prota et al, 2013). Paclitaxel, for example, mimics the nucleotide GTP and 
thus promotes stabilisation by preventing GTP hydrolysis that permits microtubule 
disassembly (Abal, 2003). 
Destabilising agents, or polymerisation inhibitors, prevent further tubulin molecules from 
being added and thus have the ability to reduce the microtubule polymer mass at high 
ĐŽŶĐĞŶƚƌĂƚŝŽŶƐ ?ŽůĐŚŝĐŝŶĞĂŶĂůŽŐƵĞƐďŝŶĚƚŽƐŽůƵďůĞɴ-tubulin creating a complex that can 
be incorporated in to the microtubule during polymerisation (see figure 1). However, the 
complex brings about a conformational change blocking further tubulin dimers from binding 
and results in disablement of the microtubule due to structural instability (Chen et al, 2009).  
In contrast, Vinca-ĂůŬĂůŽŝĚƐďŝŶĚƚŽɴ-tubulin at the Vinca-binding domain (see figure 1) of 
dimers that are already incorporated into the microtubule. They tend to bind with greater 
affinity to molecules at the ends of microtubules and this high affinity remains in low drug 
concentrations (Jordan, 2012).   
 
Figure 1. A microtubule and the binding sites of the Tubulin binding drugs. 





IV) Drug resistance   
 
Treatment failure can often be attributed to chemotherapeutic resistance of the 
Neuroblastoma cells, especially in metastatic cancers where 90% of treatment failure can 
be credited to resistance (Longley et al 2005). Drug resistance can be either intrinsic 
(previously untreated cells are unaffected by drug) or aquired (initially respond to therapy 
before developing resistance) and it is this aquired drug resistance that results in the low 
long-term suervival rates of high-risk paitents.  
It is widely understood that there are multiple durg resistance mechanisms exploited by 
cancer cells that contribute to aquired resistance. A cancer cell may have one or more of 
Figure 2. A diagram to show the mechanisms of cancer cells in resistance to tubulin-binding anti-
cancer drugs. a) Efflux of drug through the ABC transporter preventing the drug from reaching its 
target site. b) Genetic mutations affecting microtubule stability preventing binding of the drug. c) 
Alterations to tubulin and microtubules preventing the drug from binding. d) Changes to the 
cytoskeleton reduces the effect of the drug once bound. e) Changes to anti-apoptotic factors 




these mechanisms and due to the heterogenic nature of cancer, difference cells within the 
same tumour mass can have entierly different mechanisms of action. Furthermore 
Multidrug resistance can occur after treatment with a particular anti-cancer drug, resulting 
in cross-resistance to other drugs the cancer has yet to be exposed to (Ambudkar et al. 1999; 
Leslie et al. 2005). Figure 2 depics an overview of the known mechanisms involved in cancer 
cell resistance to tubulin-binding drugs.  
The first mechanism involves the efflux of the drug through ATP binding cassette (ABC) 
transporters (figure 2 a). This transmembrane transporter is involved in multiple cellular 
transport processes, including the transference of anti-cancer drugs across the cytoplasmic 
membrane. Evidence for its use as a resistance mechanisms is supported by the finding that 
multiple ABC transporters were found to be highly expressed on cancer cells (Holohan et al. 
2013).  
Genetic mutations/post-translational modifications to tubulin have also been identified as 
a resistance mechanism as they lead to increased expression of drug targets (figure 2 b). 
Though this seems counter intuitive, Holohan (2013) argues that this increase reduces the 
effectiveness of the drugs as more must bind to have the same effect as in a cancer without 
ƚŚĞƐĞŵƵƚĂƚŝŽŶƐ ?&ƵƌƚŚĞƌƚƵďƵůŝŶĂůƚĞƌĂƚŝŽŶƐ ?ƐƵĐŚĂƐƚŚĞĞǆƉƌĞƐƐŝŽŶŽĨĚŝĨĨĞƌĞŶƚɴ-tubulin 
isoforms, can result in reduced sensitivity to tubulin-binding agents. For example, the over 
ĞǆƉƌĞƐƐŝŽŶŽĨɴ///-tubulin results in a lowered efficacy of a particular tubulin-binding agent 
ĚƵĞƚŽŝƚŚĂǀŝŶŐůĞƐƐĂĨĨŝŶŝƚǇƚŚĂŶŶŽƌŵĂůɴ-tubulin (Kavallaris, 2010), depicted in figure 2 c).  
ĚĚŝƚŝŽŶĂůŵƵƚĂƚŝŽŶƐ ŝŶɶ-actin and its regulatory proteins results in changes to the cells 
cytoskeleton (Figure 2 d). This in turn has an influence on the ability of the drug to induce 




identified in cells with resistance to tubulin binding agents, as seen in figure 2 e) (Kavallaris, 
2010).  
V) Tumour Heterogeneity  
 
It is understood that cancer cells within a tumour can differ genetically from one another 
due to the increased rate of cell division and high level of mutations. It has also been argued 
that this heterogeneity can be further effected by the selection pressures from anti-cancer 
drugs that favour the less sensitive cells.  In short, the continuous formation of mutations 
give rise to a heterogeneous cell population which when introduced to drug treatments, 
exerts selective pressures that favour more resistance cells resulting in a process that 
develops resistant called clonal evolution.  
VI) Aims 
 
The two main aims of the project are as follows. Firstly, we aim to better understand Intra-
tumour heterogeneity by investigating the drug sensitivity profiles of non-resistant UKF-NB-
3 clones. And secondly, we aim to understand acquired drug resistance through the 
establishment of resistant UKF-NB-3 cell lines through adaptation using a standardised 
protocol. Specifically, this Thesis will focus on establishing and standardising the protocol 









The MYCN-amplified neuroblastoma cell line UKF-NB-3, was established from a bone 
marrow metastasis of a patient with stage 4 neuroblastoma (Kotchetkov et al., 2003).  The 
drug-resistant sub-lines and single-cell derived clones of UKF-NB-3 were derived from the 
resistant cancer cell line (RCCL) collection 
(www.kent.ac.uk/stms/cmp/RCCL/RCCLabout.html). Drug-resistant UKF-NB-3 sub-lines 
have been established as previously described (Kotchetkov et al., 2003 Michaelis et al. 2011).  
II) Reagents 
 
500mL IscŽǀĞ ?ƐDŽĚŝĨŝĞĚƵůďĞĐĐŽ ?ƐDĞĚŝƵŵ ?/DD ? ? ? ? ?/h ?ŵ>ƉĞŶŝĐŝůůŝŶĂŶĚ ? ? ?ŵŐ ?ŵ>
streptomycin were supplied by Life technologies (Paisley, UK) and foetal bovine serum (FBS) 
was obtained from Sigma-Aldrich (Ayrshire, UK).   
Phosphate Buffered Saline (PBS) was prepared by dissolving one PBS salt tablet (Oxoid 
Limited, Hampshire, UK) in 100mL of ddH2O. The solution was then sterilised using an 
autoclave and aliquoted as needed before being stored at 2oC-4oC. Trypsin and EDTA, was 
purchased from Life Technologies (Paisley, UK)  
Sodium Dodecyl Sulphate (SDS) was obtained from Fisher Scientific (Loughborough, UK). SDS 
solution was prepared by dissolving 200g SDS powder in a mixture of, 400mL of purified 
water (Barnstead NANOpure Diamond) and 400mL of dimethylformamide (DMF; Fisher 





500mg of 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT; Universal 
Biologicals, Cambridge, UK) was dissolved in 250mL of PBS prior to sterile filtration in a 
laminar flow hood using a 0.22µM bottle-top filter ( ) and a vacuum pump. The MTT solution 
was stored between 2oC-4oC and protected from sunlight.  
Dimethyl Sulphoxide (DMSO) and 0.04% trypan blue solution were purchased from Sigma-
Aldrich (Ayrshire, UK). 
III) Drugs 
 
Combretastatin A4, 2-methoxystradiol, vincristine, vinblastin, docetaxel and epothilone B 
were obtained from Cambridge Biosciences (Cayman Chemicals, USA). All compounds were 
stored as a stock solution at 1mg/mL in DMSO, except for paclitaxel which was diluted in 
ethanol (Fisher Scientific, UK). L181.1 and L181.2 were obtained from Dr Maxwell Casely-
Hayford (Medway School of Pharmacy, Universities of Kent and Greenwich, Chatham, UK.  
IV) Cell Passaging 
 
The cells grew in T25 flasks at a ratio of 1 in 10 in an environment of 37oC and 5% CO2. When 
the cells reached about 70% confluency, the cell culture medium (IMDM supplemented with 
10% FBS, 1% penicillin and 1% streptomycin) was removed and the cells were washed using 
2mL of PBS. Then, the cells were incubated for 1-2 minutes in 1mL of Trypsin (0.05%, 
w/v)/EDTA (0.02%, w/v) solution at 37oC and 5% CO2 in order to detach the cells from the 
bottom of the flask. Next, the cells were then resuspended in 9mLs of pre-warmed cell 
culture medium. The cells were transferred into a new flask. The splitting rates ranged from 





V) Cell count  
 
20µL cell suspension was mixed with 40µL of trypan blue solution and 20µl PBS and then 
counted in a haemocytometer (Hawksley; Lancing, UK). Viable (unstained) cells were then 
counted under a microscope at 40x magnification.  
 
VI) Cell Viability Assay  
 
MTT assays were performed in 96-well plates (Greiner Bio One Ltd; Stonehouse, UK) as 
previously described (Kotchetkov et al., 2003; Michaelis et al. 2011). 100µL of cell cultured 




Then, 50µL of cell suspension were added to the wells serving as untreated cell control and 
to the wells in which the cells were grown in the presence of drug (figure 4). If not indicated 
otherwise, 5000 cells/well were used.   
 
Figure 3 A schematic of where media is added in a 96 well plate. The wells 2B-2G (negative control wells) were used as cell only 
controls. The wells 11B-11G (positive control wells) were used to determine the minimum value indicating the level of background 
absorbance created by the presence of cell culture medium in the absence of cells. Different colours indicate a difference between 
the wells. 
Wells 1 2 (-ve) 3 4 5 6 7 8 9 10 11 (+ve) 12
A
B 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL
C 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL
D 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL
E 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL
F 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL
G 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL 50µL
H
Figure 4 A schematic of where cells are added in a 96 well plate. Wells 2B-2G were used as cell only control wells to determine maximum 
value when incubated without drug. Different colours indicate a difference between the wells. 
Wells 1 2 (-ve) 3 4 5 6 7 8 9 10 11 (+ve) 12
A 100µL 100µL 100µL 100µL 100µL 100µL 100µL 100µL 100µL 100µL 100µL 100µL
B 100µL 50µL 100µL 100µL
C 100µL 50µL 100µL 100µL
D 100µL 50µL 100µL 100µL
E 100µL 50µL 100µL 100µL
F 100µL 50µL 100µL 100µL
G 100µL 50µL 100µL 100µL





In a separate drug block (Corning Inc. New York, USA), 8 point serial drug dilutions were 
prepared. If not stated otherwise, 1 in 4 dilution steps were applied. 50µL of each drug 
dilution were added to the respective wells (figure 5). The arrangement of 96 well plates 
allowed for two drugs to be tested against one cell line at any one time. It also allowed for 
triplicates of each drug to be achieved.   
 
 
The plates were incubated for 120hrs at 37oC and 5% CO2. Then 25µL of MTT reagent were 
added to all wells, prior to a further incubation period of four hours. Then 100µL SDS 
solution was added and the cells were incubated over night at 37oC and 5% CO2 in order to 
dissolve the non-soluble Formazan salt that was formed through MTT metabolisation in the 
mitochondria. The absorbance was measured at 600nm using a BMG Labtech Fluostar 
Omega plate reader (Ortenberg, Germany).  
 
VII) Data analysis  
The cell viability of drug-treated cells was determined relative to untreated control 
according to the following formula: 
The concentrations that reduced cell viability by 50% IC50 or 90% IC90 were determined 
using Calcusyn (Biosoft; Cambridge, UK).     
  
Figure 5 A schematic of where the drugs are added in a 96 well plate. The concentrations are in nM. The starting concentrations of 100nM 
and 50nM are examples of possible 8 point, 1 in 4 drug dilutions and the starting concentration depend on the drug being added. 50µL of 
drug were added to each well.  
Wells 1 2 (-ve) 3 4 5 6 7 8 9 10 11 (+ve) 12
A
B 100 25 6.25 1.5625 0.390625 0.097656 0.024414 0.006104
C 100 25 6.25 1.5625 0.390625 0.097656 0.024414 0.006104
D 100 25 6.25 1.5625 0.390625 0.097656 0.024414 0.006104
E 50 12.5 3.125 0.78125 0.195313 0.048828 0.012207 0.003052
F 50 12.5 3.125 0.78125 0.195313 0.048828 0.012207 0.003052









5.  Results 
 
I) Sensitivity of the clonal UKF-NB-3 sub-lines to tubulin-biding 
agents 
 
The clonal UKF-NB-3 sub-lines were tested for sensitivity to the tubulin-binding agents 
Combretastatin A4 and 2-Methoxyestradiol (microtubule destabilising agents targeted to 
the colchicine domain), Vincristine and Vinblastine (microtubule destabilising agents 
targeted to the vinca-domain), and Docetaxel and Epothilone B (microtubule stabilising 
agents that target the taxoid domain). The drugs L181.1 and L181.2 (novel Combretastatin 
A4 derivatives) were also screened against the clonal UKF-NB-3 sublines. 
In order to detect differences in the drug sensitivity of the individual clones, we determined 
the mean IC50 of a drug in all clones. Then we identified clones in which the IC50 was >2-
fold higher or lower than the mean. In addition, we identified >2-fold differences between 
the individual clones. 
The Combretastatin A4 IC50  values of the investigated clones range from 0.24nM to 0.55nM 
(figure 6a). This is similar to the Combretastatin A4 IC50 in the UKF-NB-3 cell line (0.4nM ±  
0.05nM). The mean IC50 value was 0.24nM. Only clones 4 and 7 displayed an IC50 value that 




The IC50 values for the Combretastatin A4 derivatives L181.1 and L181.2 means ranged from 
55nM to 82nM (Figure 6b) and 175nM to 336nM (Figure 6c) respectively. Though all three 
sets of data  appear to have the same slightly variable IC50 pattern amongst the clones, the 
amount of drug required to reach the IC50s for L181.1 and L181.2, when compared to that 
required for Combretastatin A4, are notably higher with up to a 200-fold and 1000-fold 
increase respectively (Table 2).  This shows that the derivatives have a lower molecular 
potency. Interestingly, all of the individual data points for both drugs lie within a 2-fold range. 
The IC50 for clone 7, however, was >2-fold lower than the mean IC50 but only very slightly 







Clone 1 0.24nM±0.15nM 55.23nM±16.11nM 230.13 249.10nM±88.58nM 1037.92 
Clone 2 0.37nM±0.2nM 66.19nM±25.22nM 178.89 306.03nM±65.75nM 827.11 
Clone 3 0.37nM±0.05nM 57.61nM±23.77nM 155.86 175.44nM±44.91nM 474.16 
Clone 4 0.55nM±0.55nM 82.44nM±22.96nM 149.89 336.37nM±77.46nM 611.58 
Clone 7 0.53nM±0.14nM 72.78nM±29.15nM 137.32 264.42nM±90.99nM 498.91 
Table 2. Comparison of IC50 values of Combretastatin A4 and its two derivatives, L181.1 and 
L181.2, of all clonal sub-lines and the relative differences between each derivative and 
Combretastatin A4. The data shows the relative potency of Combretastatin A4 to its two derivatives.  








The IC50s for the drug 2-methoxyestradiol can be seen in figure 6d. Though no significant 
data was identified, the ranges between the individual data points for each clone differ 
dramatically, suggesting a high amount of variability between the clones. Clones 1 and 3 had 
the least amount of variability, with the data ranging from 366.69nM and 592.23nM 
respectively, while clones 2, 4 and 7, however, had large ranges of 1610.87nM, 3216.77nM 
and 1187.83nM.  
Figures 6e and 6f, depict the IC50s of the vinca-alkaloid drugs, vincristine and vinblastine. 
The IC50 values of the clones are almost identical when you compare the two drugs, 
suggesting similar properties. The data could also suggest that the clones retained the same 
anti-cancer drug resistance mechanisms. The cumulative data of all clones from both drugs 
showed no significant differences. Individually, when testing vincristine, Clones 2 and 3 
showed some data points that did not fall in the two-fold ranges (2 and 1 respectively), while 
for Vinblastine clones 1 had 4 IC50s, 3 which were <2- and 1 which was >2-fold difference, 
and clone 2 had 2 less and 1 greater than a 2-fold difference. Again, as seen with most of 
ƚŚĞĚƌƵŐƐ ?ƚŚĞĚŝĨĨĞƌĞŶĐĞƐĂƌĞŶ ?ƚǀĞƌǇůĂƌŐĞƐŽĚŽŶŽƚƌĞĂƉĂƐŝŐŶŝĨŝĐĂŶƚƌĞƐƵůƚ ? 
The figure 6g, showing the IC50 values for Docetaxel (range of 0.2nM to 0.55nM), again 
shows no significant differences between the clones. However the data points range 
significantly between clones, with clone 1 having a range of 0.05965nM while clone 2 has a 
range 10-fold greater at  0.5775nM 
Again, figure 6h, depicting the mean IC50 range of 0.05nM-0.11nM, no significant 
differences between the clones when testing Epothilone B. However the data does support 
the finding that Epothilone B has increased efficacy compared to Docetaxel, as the mean 
IC50s  of all the clones have a <4.5-fold increase from Epothilone B to Docetaxel, though the 




II) Adaptation of UKF-NB-3 to Paclitaxel by a standardised protocol 
 
In order to investigate resistance acquisition in UKF-NB-3 cell lines a protocol was developed 
in order to standardise the way in which resistant cell lines are developed. The aim is to 
create comparable resistant cell lines to different drugs that will allow for the possible 
identification of cross-resistance.  This is a long term study that began before I started my 
masters project and involves the adaptions of UKF-NB-3 to multiple tubulin-binding agents. 
As a result, I did not complete the first 17 weeks of work on the project and I only collected 
data from the cell lines adapted to the tubulin stabilising agent, Paclitaxel. 
The protocol consists of exposing the 10 sub-lines of UKF-NB-3 cells to the previously defined 
IC50 concentration of paclitaxel (0.57nM), on alternate weeks. In these weeks, the number 
of cells required for incubation with the drug was 100,000 cells/ml, while in weeks were 
there was no drug, only 10,000 cells/ml was essential.  At the end of each week the number 
of remaining cells was determined allowing the calculation of the fold-difference between 
the number of cell at the start and after a 168 hour incubation period. 





 Figure 7. The number of cells per mL after each 168 hour incubation in either the presence (+) or absence 
(-) of 0.57nM Paclitaxel for cell lines 1-10.  In week without drugs, the starting number of cells was 
10,000/ml and for the weeks where drug was added, 100,000 cells/ml were required. From week 29 
onwards, 10,000 cells/ml were added regardless. Cell line 5 was lost in week 7, followed by the loss of cell 
lines 3 and 4 in week 41 and cell lines 2,6 and 10 in week 42. No data was collected in week 12 and only 




While both graphs in the figure show the same set of data, 7a, allows the visualisation of 
the general change in cell number of the cell line UKF-NB-3 over the continuous weeks. The 
most observable trend (which can be seen in both figure 7a and 7b) is the initial decline in 
the cell number in weeks where the cells were incubated with the drug. This is most likely 
down to the chemotherapeutic effects of the drug. However, from week 16 onwards, the 
number of cells counted when incubated with drug was higher than that counted in the drug 
free weeks. This suggests that the cells were becoming increasingly resistant to paclitaxel 
and the higher cell number reflects the 10-fold increase in the cell number incubated in 
those weeks.  
Figure 7b, on the other hand, allows a clearer look at the number of cell of each individual 
sub-line and how they differ from week to week. One interesting finding is that the number 
of cells counted for cell line 1 remains consistently higher than the other cell lines 
throughout the study, along with cell lines 9 and 10 (see raw data in Appendix). However, 
the higher IC50 values do not directly correlate with cell line survival since cell line 10 was 
lost in week 42. Moreover, cell line 8 generally had lower cell numbers relative to the over 
sub-lines, but when the cells were passaged, cell line 8 always out grew the other cell lines 
with it often achieving the highest confluence.  
The data from both graphs shows a general decline in the number of cells in both the weeks 
with and without drug, as the duration of the study lengthens. The high cell numbers of the 
cell line in week 39 are explained by construction works during which the lab could not be 





Figure 8 The fold difference between the cell number at 0 hours and the number of cells after 168 hour 
incubation for all 10 cell lines.  In week without drugs, the starting number of cells was 10,000/ml and for 
the weeks where drug was added, 100,000 cells/ml were required. From week 29 onwards, 10,000 cells/ml 
were added regardless. Cell line 5 was lost in week 7, followed by the loss of cell lines 3 and 4 in week 41 
and cell lines 2,6 and 10 in week 42. No data was collected in week 12 and only for half the cell lines in 




Figure 8 a and b (also see Appendix II b)-d)), depict the fold-difference in cell number 
between the number of cells incubated at the beginning of each week and the resulting cell 
number after the incubation period. Again figure 8a,  shows the general trend of the change 
in cell number across the weeks, while figure 8b,  allows the comparison of individual data 
points. By calculating the fold difference, the change in cell number from the beginning of 
the incubation and the end, is observable and thus a clearer picture of the effect of paclitaxel 
on the resistance adaptation of each cell line can been seen. To better understand the effect 
the new protocol was having on the cells as a whole, the data was separated into weeks 
with drug and weeks without. The two new sets of data were then split in to 3 sections, each 
depicting a different phase in the study which can be visually identified in figure 8a. The first 
groups were weeks 1-15 (no drug) and 2-14 (with drug), showing the initial phase, the 
second groups were weeks 17-29 (no drug) and 16-28 (with drug) where the growth began 
to change and the final section contained the remaining weeks 31-47 (no drug) and 30-46 
(drug). The mean fold-difference was then identified for each week and thus the mean for 
each section was then determined (see Table 3 and Appendix II e)). By analysing the data in 
this way the general effect across all cell lines can be observed. 
 Without Paclitaxel 0.57nM Paclitaxel 
Weeks 1-15 17-31 33-47 2-14 16-28 30-46 
Mean 154.0625 18.05625 42.4375 6.08 13.94429 26.6111111 
STDV 54.34077494 20.39655083 62.49760995 3.104835 1.689604 15.1541615 
This data shows that initially, there is a greater fold increase (154-fold ±54) when the cell 
lines were incubated without drug, while in the presence of the drug, there is only a small 
increase of 6-fold (±3), again supporting the idea that Paclitaxel is having anti-proliferative 
effect on the cells. However, from week 16 onwards, there is an increase in the fold 
difference of cells in the presence of the drug, where the average increase of all cell lines is 
Table 3. The analysis of the individual cell lines as a whole, grouped depending on the 




14-fold (±2). This further continues in to the remaining weeks where the mean fold 
differences average at 27 (±15). This data shows that, even when the cell number is reduced 
at the beginning of the incubation, as the weeks were the drug is present go by, the greater 
the difference in cell number, meaning their ability to grow in the presence of the drug   
increases. 
Interestingly, when there is no drug, the general fold-difference dramatically decreases to 
18-fold (±20) after week 17, suggesting a reduced ability to grow after incubation with 
paclitaxel. The growth picks up again, however, but remaining lower than at the beginning 
of the study, with the average increase in the cell number of 42-fold (±62). This indicates 
that the cells are becoming adapted to the growing conditions and thus becoming for 
resistant to the effects of paclitaxel.   
Understanding the growth of the cell lines is important as it gives an indication to how well 
the cells have adapted to the drug due via increased growth. However, it does not give a 
quantifiable value that enables comparison to other cell lines etc. In order to gage the 
resistance profile of the cell lines, an MTT assay was performed every 4 weeks, resulting in 
the generation of IC50 values for each cell line, as depicted in figure 9 . Unfortunately, as 
the project changed hands, MTTs were unable to be conducted, resulting in a gap in the data 




In the initial screening in week 4, all cell lines showed an increase in their IC50 values when 
compared to the IC50 of a UKF-NB-3 cell line (0.57nM). Though, a slight lowering of the IC50s 
can be seen during week 8, in general, the IC50s stayed constant, with most cell line IC50s 
not reaching above 1nM. This indicates that the exposure to paclitaxel creates initial 
resistance but as no results had a >2-fold difference compared to UKF-NB-3, the findings do 
not count as noteworthy. 
 
However, this is not the case for cell line 8 which shows an increase in its IC50 from week 30 
onwards where it reaches its peak in week 45 in which it takes 3.25nM of paclitaxel to reduce 
cell viability by 50%. These results are greater than a 2-fold difference when compared to 
the original cell line. This trend in cell line 8 can be seen more clearly in figure 10 (also see 
appendix II h)). The figure shows that though the IC50s of all cell lines increase above that 
Figure 9 Drug concentrations at which cell viability is reduced by 50% (IC50) for each of the 10 UKF-NB-3 
cell lines adapted to 0.57nM of Paclitaxel, as determined by MTT assay after a 120 hour incubation. Cell 
line 5 was lost in week 7, followed by the loss of cell lines 3 and 4 in week 41 and cell lines 2,6 and 10 in 
week 42. No data could be collected for cell lines 1-4 and 6 from the MTT assay run in week 30, as well as 




of the sensitive UKF-NB-3 cell line, the IC90s remain the same. Again this is not the case for 
cell line 8, where its IC90 increases >2-fold higher than that of the parental cell line (0.99nM) 
from week 30. The comparison of just cell line 8 can be found in the Appendix II i)). 
 Though it appears that when UKF-NB-3 sub-lines are incubated with paclitaxel on alternate 
weeks, their IC50s increase and thus appear to be resistance, due to the lack of statistically 
significant data this cannot be concluded. However, striking data is generated in the final 
weeks for cell line 8, with a substantial increase in the IC90. Furthermore, the addition of 
fluctuating cell numbers depending on whether or not the drug is present, seems to allow 
time for the cell lines to recoup, thereby reducing the number of cell lines lost though out 
the adaptation process. 
  
Figure 10. Comparison of drug concentrations at which cell viability is reduced by 50% (IC50) and 
90% (IC90) of all 10 UKF-NB-3 Paclitaxel adapted cell lines over 8 weeks of MTT assays of 120 hour 




 6. Discussion  
 
I) Sensitivity of the clonal UKF-NB-3 sub-lines to tubulin-biding 
agent 
 
UKF-NB-3 is a MYCN-amplified Neuroblastoma cell line. 5 single cell derived clones  (1,2,3,4 
and 7) were then produced to study intra-tumour heterogeneity, with the aim of 
determining the effects on the sub-lines after inoculation with a panel of tubulin-binding 
agents. These include the microtubule destabilising agents Combretastatin A4 and 2-
methoxestradiol (bind to the colchicine domain) and Vincristine and vinblastine (that bind 
to the vinca-domain), as well as the microtubule stabilising agents docetaxel and Epothilone 
B (that bind to the taxoid domain). The drugs, L181.1 and L181.2, which are derivatives of 
Combretastatin A4 were also screened against the clonal UKF-NB-3 sub-lines, though their 
mechanism of action is at this point, still unknown.   
We found that the data suggest some heterogeneity. Though there were no significant 
results, the difference between the cell lines can be clearly seen in the level of the spread of 
data and the high value ranges. It suggests that there was no uniformed repose to the drugs. 
It also highlights the heterogeneity within the sublines. For example, when looking at the 
raw data for the clones tested against 2-methoxyestradiol, the IC50s change dramatically 
from one week of testing to the next.  
The data highlights just how difficult it is to experimentally determine the effects of anti-
cancer drugs on the cells. Often when analysing resistance data, a standard value is used to 
determine the IC50 of the sensitive cell lines. However our data shows that even sensitive 




valid. The data highlights the need for control (sensitive) cell lines to be tested alongside 
experimental cells in order for the results to be comparable.  
It is important to note that this clonal work is only a small part of a larger project going on 
in the lab and that this data was collected in order to make comparisons between sensitive 
clones and clones from a resistance subline. This work was undertaken by others within the 
lab and will be analysed properly when all the data is collected. It is for this reason I cannot 
say much about the data other than the fact that there were on clearly defined observable 
differences.  
 
II) Adaptation of UKF-NB-3 to Paclitaxel by a standardised protocol 
 
To further understand the effects of drug induced heterogeneity, we adapted 10 sub-lines 
of UKF-NB-3 to the microtubule stabilising drug, Paclitaxel.  The aim was to devise and test 
a new standardised protocol for the adaption of cell lines to anti-cancer drugs that would 
allow the further study and understanding of drug-induced resistance. The aim was to study 
the drug-induced heterogeneity in a given cancer cell population using a cancer cell line as 
a model. An additional aim was to develop standardised drug adaptation protocols that 
enable the comparison of drugs for their potential to induce resistance in a given cancer cell 
population.  
Our protocol, focuses on alternating drug incubation with UKF-NB-3 cells, compared to most 
adaptation protocols where cells are continuously exposed to the drug in question. Here, 
we incubated 10,000 cells/ml for all ten cell lines, in the absence of Paclitaxel. Following a 
168hour incubation, the cells were passaged, this time inoculating 100,000 cells/ml in the 




viability by 50% in the cell line UKF-NB-3. After a further 168 hour incubation, the original 
growing conditions were reinstated and this continued until the 29th week where it was 
decided that the remaining 9 cell lines (cell line 5 was lost in week 7) would be passaged 
with 10,000 cells/ml regardless of whether the drug was present or not. This decision was 
made because, when incubated with the drug and thus 100,000 cells/ml, the cells to reached 
the ideal passaging confluency of 70% before the 168 hour incubation was completed. This 
resulted in a lack of viable cells for the following incubation, due to the environmentally 
stressful conditions they were subjected to. Though I completed analysis on the cells after 
the 47th week, the study is still ongoing. Also, though I analysed all 47 weeks, I took over the 
passaging of the cells from the 18th week onwards.  
We found that through using a standardised drug adaptation protocol, heterogenic cellular 
sub-lines were created with resistance to Paclitaxel.  
The need for a protocol like this enables the study of resistance formation, where it was not 
previously possible. Currently, to achieve this, regular biopsies must be taken from a patient 
which is neither possible to practically achieve nor is it fair or ethical for the patient. 
&ƵƌƚŚĞƌŵŽƌĞ ?ďŝŽƉƐŝĞƐĚŽŶ ?ƚĂůůŽǁĨŽƌƚŚĞŽǀĞƌĂůůǀŝĞǁŽĨƚŚĞĐĂŶĐĞƌĂƐŽŶůǇĂƐŵall number 
of cells are sampled from one section of the cancer. By having a protocol which is known to 
appropriately adapted cells to a particular drug, it will reduce the need for patient biopsies. 
 The protocol will also allow for the comparison of cross resistance with drugs of a similar 
and different mode of action. This has therapeutic implications as it will allow for quicker 
and more effect treatment strategies as clinicians will be able to suggest the appropriate 
drug for a patient with a known drug resistance. By creating a catalogue of resistance 
profiles and cross-resistance profiles the ideal treatment course can be suggested, reducing 




There are current protocols for drug resistance adaptation but these focus on continuous 
exposure to the drug in question instead of alternating incubations (Biedler J. L. et. al. (1970); 
Liang X. J. et al (2003)). This method of resistance formation also tends to result in the early 
loss of cell lines as the sensitive cells are killed by the drug. With the weekly changing cell 
number we implicate here, this early loss of cell lines are overcome.  
Though assessing cells through a viability assay allows an insight as to the resistance profile 
of the sub-lines and though this can be compared to the other sub-lines and even other cell 
lines, it is not possible to understand what is going on at a molecular level. This means the 
true heterogenic nature of the sub-lines cannot be established. To achieve this, I would 
suggest in future experiments that samples are taken at regular intervals and subjected to 
genetic analysis to better understand what is going on within the cells. For example, testing 
for certain cell surface receptors etc. to define what resistance mechanisms are being 
utilised my each cell line. This will also be advantageous in a clinical setting, as once these 
are determined, the appropriate drugs can be suggested that are known to bypass the 
pathway in question.  
&ƵƌƚŚĞƌŵŽƌĞ ?/ ?ĚƐƵŐŐĞƐƚƵŶĚĞƌƚĂŬŝŶŐŽƚŚĞƌǀŝĂďŝůŝƚǇ ĞƐƚŽƚŚĞƌƚŚĂŶũƵƐƚĂŶDddĂƐƐĂǇ ?dŚŝƐ
is because MTT assays assess metabolic activity of the cells, a process which can be slowed 
in living cells though because of the way the assay is completed, can often identify this cells 
ad dead when they are not. In short, the assay cannot differentiate between anti-
proliferating cells and those that have under gone apoptosis. Also the viability assays could 
be performed more regularly than every four weeks to get a clearer understanding 
resistance acquisition. However, there are experimental constraints with this the process 
can take several hours to set up and be completed and this is only lengthened when the 




assay (Pieters et al (1989). By using this method the chances of human error effecting the 
results is reduced. 
7. References 
 
Abal M. et al (2003) Taxanes: Microtubule and centrosome targets and Cell cycle dependant 
mechanisms of action. Current cancer drug targets. 3: 193-203. 
Ambudkar S. et al (1999) Biochemical, cellular, and pharmacological aspects of the multidrug 
transporter RID B-5964-2008. Annual Review of Pharmacological Toxicology 39: 361-398. 
Anderson D. et al (1991) Antibody markers identifying a common progenitor to sympathetic 
neurons and chromaffin cells in vivo and reveal the timing of commitment to neuronal 
differentiation in the sympathoadrenal lineage. Journal of  Neuroscience 11: 3507-3519. 
Biedler J.L. et al (1970) Cellular Resistance to Actinomycin D in Chinese Hamster Cells in vitro: 
Cross-Resistance, Radioautographic, and Cytogenetic studies. Cancer Research 30: 1174-1184 
Brodeur G. M. (2003) Neuroblastoma: biological insights into a clinical enigma. Nature 
Review Cancer 3: 203-216.  
Chen J. et al (2009) Recent development and SAR analysis of Colchicine binding site 
inhibitors. Mini-reviews in medicinal chemistry 9: 1174-1190. 
Cheung N. K. et al (2013) Neuroblastoma: developmental biology, cancer genomics and 
immunotherapy. Nature Review Cancer 13: 397-411. 
D'Angio G. J. et al (1971) Special pattern of widespread neuroblastoma with a favourable 
prognosis. Lancet 1: 1046-1049. 
Etienne-Manneville S. (2010) From signalling pathways to microtubule dynamics: the key 
players. Current opinion in Cell Biology 22: 104-111. 
Gottesman M. M. et al (2006) Defeating drug resistance in cancer. Discovery Medicine 6: 18-
23. 
Holohan C. et al (2013) Cancer drug resistance to tubulin-binding agents. Nature Review 
Cancer 10: 714-726. 
Howard J. et al (2007) Microtubule polymerases and depolymerases. Current opinion in Cell 
biology 19 : 31-35. 
Jordan M. (2012) Mechanisms of action of antitumor drugs that interact with microtubules 




Kavallaris M. (2010) Microtubules and resistance to tubulin-binding agents. Nature Reviews 
Cancer 10: 194-204. 
Kotchetkov R. (2003) Development of resistance to vincristine and doxorubicin in 
neuroblastoma alters malignant properties and induces additional karyotype changes: a 
preclinical model. International journal of cancer 10;36-43 
Liang X. J. et al (2003) Mislocalization of Membrane Proteins Associated with Multidrug 
Resistance in Cisplatin-resistant Cancer Cell Lines. Cancer Research 63: 5909 
Leslie E. et al (2005) Multidrug resistance proteins: Role of P-glycoprotein, MRP1, MRP2, 
and BCRP (ABCG2) in tissue defence. Toxicology and applied Pharmacology 204: 216-237. 
Longley D. B. et al (2005) Molecular mechanisms of drug resistance. Journal of Pathology 
205: 275-292. 
Maris J. M. et al (2002) Evidence for a hereditary Neuroblastoma predisposition locus at 
chromosome 16p12-13. Cancer Research. 62: 6651-6658. 
Maris J. M. et al (2007) Neuroblastoma. Lancet 369: 2106-2120. 
Michaelis M. et al (2011) Adaptation of cancer cells from different entities to the MDM2 
inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells. 
Cell Death and Disease. 2: 1-8  
Morris P. G. et al (2008) Microtubule Active Agents: Beyond the Taxane Frontier. Clinical 
Cancer Research 14: 7167 
Mosse Y. P. et al (2004) Germline PHOX2B mutations in hereditary neuroblastoma. The 
American Journal of Human Genetics 75: 727-730. 
Nickerson H. J. et al (2000) Favorable biology and outcome of stage 4S neuroblastoma with 
supportive care or minimal therapy: a Children's Cancer Group study. Journal of Clinical 
Oncology 18: 477-486. 
Pieters R. et al (1989) Comparison of the rapid automated MTT-assay with a dye exclusion assay for 
chemosensitivity testing in childhood leukaemia. British Journal of Cancer 59: 217-220 
Prota A. E. et al (2013) Molecular mechanism of action of microtubule stabilizing anti-cancer 
agents. Science 339: 587-590. 
Quinn J. J. et al (1979) The multiple hematological manifestation of Neuroblastoma. The 
American Journal of Pediatric Hematological-oncology 1: 201-205. 
Ries L. A. G. et al (2007) SEER Cancer Statistics Review, 1975-2004, National Cancer 






8.  Appendix 
 
I) Sensitivity of the clonal UKF-NB-3 sub-lines to tubulin-biding 
agent 
a) Clonal UKF-NB-3  MTT assay raw data 
 
 
Clone 1 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.14897 0.18749 49.38247 68.55376 318.6081 441.4491 487.5684 672.3367
0.11134 0.15021 88.34911 266.62 184.9381 308.799 854.2541 2796.847
0.1375 0.25861 32.39066 310.6975 147.8318 380.4975 603.7796 1222.287
0.1176 0.91184 48.09395 102.0231 134.7334 184.2196 814.9076 1430.274
0.13822 0.18678 49.12855 68.28539 316.0976 490.5753
0.40166 0.55539 56.08728 75.53245 315.2895 437.9436
0.46501 0.62092 54.54444 73.94514 326.0883 449.3189
0.43979 0.5951 63.85189 165.3963
0.20127 0.47434
Mean 0.240151 0.437853 Mean 55.22854 141.3817 Mean 249.0838 384.6861 Mean 690.1274 1530.436


































Clone 1 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.07542 0.13177 0.02359 0.04342 0.18092 0.11871 0.1057 0.1782
0.05431 0.55714 0.02078 0.07061 0.17392 0.23598 0.06392 0.08343
0.06558 0.11858 0.03301 0.0766 0.22517 0.46833 0.05941 0.07891
0.14495 0.21556 0.03973 0.07875 0.23357 0.52282 0.10765 0.14641
0.08172 0.1797 0.10501 0.13621
0.0203 0.07554 0.03052 0.23843
0.13377 0.2243 0.02757 0.06441
Mean 0.085065 0.255763 Mean 0.050414 0.106989 Mean 0.203395 0.33646 Mean 0.071397 0.132286






























Clone 2 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.63256 1.35713 105.4617 155.002 344.6278 468.6414 721.2361 1552.073
0.21657 0.3554 56.11809 78.1146 349.44 473.6159 2332.106 3081.587
0.13479 0.18951 53.27577 72.63186 295.1211 416.4452 1202.524 8239.646
0.16027 0.29832 37.74916 50.22972 164.4761 266.4966 1837.484 2557.72
0.43625 0.59146 87.88626 232.5356 351.1456 475.3751
0.54633 1.0243 56.66459 76.12372 323.7453 446.8586





Mean 0.366332 0.606173 Mean 66.1926 110.7729 Mean 306.0283 426.2333 Mean 1523.337 3857.756





































Clone 2 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.04766 0.06327 0.07235 0.17084 0.21441 0.21441 0.05178 0.07108
0.02448 0.05203 0.02258 0.07302 0.79191 1.31497 0.05348 0.07285
0.03972 0.05507 0.22214 0.30921 0.48613 0.83612 0.06041 0.07993
0.06121 0.10606 0.05944 0.08246 0.08867 0.13349
0.03155 0.05234 0.18775 0.31409 0.08475 0.1157




Mean 0.061724 0.104919 Mean 0.098375 0.170503 Mean 0.497483 0.7885 Mean 0.067818 0.09461






























Clone 3 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.36493 0.50797 54.66705 74.07168 244.2089 425.5668 355.1614 628.0094
0.40848 1.00643 113.9389 139.4645 181.4269 305.2839 947.3902 1616.651
0.32327 0.53388 48.00662 67.84123 196.0916 407.9404 715.4084 1310.921
0.35278 0.93666 33.60468 45.97296 128.0119 177.1792 742.3052 1836.539
0.31456 0.52264 51.5068 70.78815 124.1326 228.4749
0.43878 0.59406 54.37091 73.76594 178.7628 298.1034
0.39547 0.54887 51.15159 70.41612
53.65113 73.02119
Mean 0.371181 0.664359 Average 57.61221 76.91772 Average 175.4391 307.0915 Average 690.0663 1348.03


































Clone 3 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.07605 0.13193 0.02702 0.04719 0.3125 0.36869 0.05809 0.07757
0.03524 0.04905 0.0623 0.12272 0.65749 0.87732 0.05538 0.07481
0.03955 0.05489 0.02313 0.0709 0.67247 0.91985 0.09766 0.11522
0.02371 0.09681 0.06084 0.10189 0.11232 0.18414
0.02646 0.05128 0.02826 0.07501 0.09829 0.1366




Average 0.037104 0.07892 Average 0.04102 0.091978 Average 0.547487 0.721953 Average 0.096332 0.128782






























Clone 4 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.41846 0.573 95.85316 162.7126 385.1259 510.0137 533.2332 719.7684
0.24402 0.51063 97.65625 115.2165 361.1747 485.6784 3750 4424.314
0.4662 0.62213 41.72769 54.21211 381.2216 506.072 2094.302 2839.282
0.97084 1.28312 57.61294 77.09188 181.029 279.8634 2012.794 2754.746
0.49055 0.64672 97.65625 115.2165 345.2281 469.2629
0.94172 1.2537 90.82931 148.5403 364.4276 489.0056




Mean 0.554308 0.76121 Average 82.43919 117.4787 Average 336.3678 456.6493 Average 2097.582 2684.528






































b) Table to assess  Significance of the mean clone data 
Clone 4 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.15876 0.22015 0.05794 0.08142 0.19286 0.33345 0.13766 0.17627
0.04315 0.05865 0.06606 0.08936 0.15603 0.28291 0.11791 0.19435
0.04073 0.05613 0.11015 0.19434 0.19029 0.33475 0.11141 0.18396
0.04421 0.05974 0.06045 0.08353 0.11584 0.15481 0.13188 0.17088
0.08325 0.11413 0.15935 0.20231 0.31729 0.54261 0.06016 0.07967
0.05059 0.06621 0.06496 0.08822 0.32751 0.56077 0.12746 0.15787





Average 0.080229 0.11064 Average 0.086189 0.146347 Average 0.234111 0.397474 Average 0.114413 0.1605






























Clone 7 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.67773 1.19749 58.67172 78.1683 127.5841 370.402 1029.804 1757.551
0.8132 1.12117 113.4838 188.3121 314.1706 436.7597 2217.629 2965.719
0.41263 0.56691 53.743 73.11638 205.7726 332.2356 1988.043 2728.914
0.61224 1.04038 36.63241 49.09422 297.564 414.1997 1725.252 2576.114
0.6675 1.1935 119.644 250.1562 147.1275 196.9866
0.49317 0.64934 62.61558 82.13798 363.4984 488.0559
0.45318 0.60885 61.9537 94.80197 336.6599 460.3682
0.10942 0.14823 75.48866 125.1174 322.9645 446.0377
Mean 0.529884 0.815734 Average 72.77911 117.6131 Average 264.4177 393.1307 Average 1740.182 2507.074


































Clone 7 IC50 IC90 IC50 IC90 IC50 IC90 IC50 IC90
0.06478 0.13648 0.09067 0.16667 0.35212 0.61283 0.05529 0.07472
0.03131 0.05216 0.02998 0.12703 0.2666 0.45551 0.0234 0.06284
0.03705 0.05222 0.09901 0.17573 0.27947 0.4968 0.0506 0.06984
0.079 0.10968 0.06549 0.17609 0.0518 0.07109
0.04199 0.05745 0.14444 0.30909 0.05691 0.07638
0.03392 0.06108 0.05984 0.09617
0.06417 0.11761 0.0374 0.09575
0.11677 0.20623
0.05812 0.10767
Average 0.058568 0.100064 Average 0.085918 0.190922 Average 0.299397 0.521713 Average 0.047891 0.078113






























0.08507 0.05041 0.2034 0.0714
0.06172 0.09838 0.49748 0.06782
0.0371 0.04102 0.54749 0.09633 <2-fold
0.08023 0.08619 0.23411 0.11441 2-fold
0.05857 0.08592 0.2994 0.04789 >2-fold
0.03227 0.129076 0.03619 0.144766 0.17819 0.712749 0.03979 0.159141
Epothilone BDocetaxelVinblastineVincristine
0.0795703140.3563746190.0723831710.064538152
Clone 1 0.24015111 55.2285 249.084 690.127
Clone 2 0.36633182 66.1926 306.028 1523.34
Clone 3 0.37118143 57.6122 175.439 690.066
Clone 4 0.554308 82.4392 336.368 2097.58
Clone 7 0.52988375 72.7791 264.418 1411.85
Mean of all clones
2 fold range 0.12 0.4803 33.53 133.7 133.134 532.534 641.295 2565.18





 II) Adaptation of UKF-NB-3 to Paclitaxel by a standardised protocol 
a)  Weekly cell number raw data 
 
  
Week 11 - Week 12 + Week 13 - Week 14 +Week 15 - Week 16 + Week 17 - Week 18 +Week 19 - Week 20 +
Cell line 1 2420000 - 770000 380000 650000 1970000 - 2140000 530000 1560000
Cell line 2 1610000 - 880000 730000 1140000 2080000 - 1770000 360000 1330000
Cell line 3 2130000 - 1130000 450000 1590000 1950000 - 1050000 420000 1000000
Cell line 4 1850000 - 1320000 400000 1570000 1620000 - 1360000 840000 1920000
Cell line 5 - - - - - - - - - -
Cell line 6 2560000 - 620000 1020000 970000 1700000 - 1610000 540000 1170000
Cell line 7 2050000 - 970000 730000 730000 1680000 640000 830000 - 930000
Cell line 8 1620000 - 1120000 740000 1180000 1110000 1140000 1390000 - 1320000
Cell line 9 2230000 - 770000 1260000 1000000 2320000 770000 1210000 - 1020000
Cell line 10 1710000 - 1070000 870000 1160000 1760000 1040000 1750000 - 1010000
Week 1 - Week 2 + Week 3 - Week 4 + Week 5 - Week 6 + Week 7 - Week 8 + Week 9 - Week 10 +
Cell line 1 760000 900000 1790000 1020000 2450000 770000 2150000 270000 1710000 1000000
Cell line 2 500000 630000 1870000 860000 1850000 780000 2400000 320000 2610000 620000
Cell line 3 1250000 770000 1610000 880000 2100000 850000 2010000 660000 1420000 1160000
Cell line 4 870000 850000 1930000 660000 2000000 1080000 2000000 780000 1630000 930000
Cell line 5 1530000 960000 1740000 880000 1950000 180000 - - - -
Cell line 6 530000 830000 2400000 740000 2560000 540000 2830000 390000 2160000 660000
Cell line 7 450000 760000 1330000 1220000 2200000 760000 1720000 540000 2120000 700000
Cell line 8 590000 670000 2390000 520000 1570000 890000 2250000 460000 2390000 740000
Cell line 9 470000 550000 2180000 1060000 1960000 1240000 2650000 340000 1560000 1060000
Cell line 10 1290000 960000 2680000 690000 1780000 1100000 2010000 110000 2230000 640000
Week 21 - Week 22 + Week 23 - Week 24 +Week 25 - Week 26 + Week 27 - Week 28 +Week 29 - Week 30 +
Cell line 1 810000 2040000 1010000 3220000 1000000 1560000 750000 1490000 830000 350000
Cell line 2 580000 1680000 950000 2450000 1040000 1690000 950000 1720000 810000 190000
Cell line 3 750000 1750000 770000 1470000 390000 1430000 810000 1210000 720000 130000
Cell line 4 850000 1580000 1000000 1690000 810000 1320000 520000 1680000 870000 190000
Cell line 5 - - - - - - - - - -
Cell line 6 710000 1730000 860000 1020000 640000 2070000 880000 1720000 840000 570000
Cell line 7 720000 1630000 1020000 1660000 690000 1640000 840000 1800000 780000 470000
Cell line 8 1030000 1120000 730000 1030000 630000 810000 460000 560000 720000 430000
Cell line 9 710000 1490000 760000 1500000 320000 1790000 930000 1790000 980000 230000
Cell line 10 580000 1100000 510000 1850000 980000 1150000 630000 1610000 840000 270000
Week 31 - Week 32 + Week 33 - Week 34 +Week 35 - Week 36 + Week 37 - Week 38 +Week 39 - Week 40 +
Cell line 1 220000 500000 380000 380000 250000 70000 110000 240000 2060000 370000
Cell line 2 380000 400000 460000 80000 330000 50000 250000 730000 2280000 90000
Cell line 3 530000 540000 290000 120000 30000 80000 570000 520000 2040000 70000
Cell line 4 450000 340000 230000 210000 80000 150000 960000 640000 1410000 50000
Cell line 5 - - - - - - - - - -
Cell line 6 150000 530000 370000 150000 140000 30000 220000 590000 2460000 150000
Cell line 7 - 470000 240000 220000 580000 180000 360000 210000 2530000 770000
Cell line 8 570000 350000 540000 140000 180000 210000 460000 770000 1440000 220000
Cell line 9 430000 240000 250000 - 180000 450000 220000 1190000 2760000 980000
Cell line 10 440000 270000 150000 820000 390000 160000 550000 1040000 2420000 230000
Week 41 - Week 42 + Week 43 - Week 44 +Week 45 - Week 46 + Week 47 -
Cell line 1 230000 1190000 160000 650000 280000 160000 1200000
Cell line 2 20000 - - - - - -
Cell line 3 - - - - - - -
Cell line 4 - - - - - - -
Cell line 5 - - - - - - -
Cell line 6 10000 - - - - - -
Cell line 7 200000 440000 190000 100000 70000 80000 1290000
Cell line 8 40000 20000 140000 410000 460000 370000 500000
Cell line 9 110000 1050000 190000 540000 110000 110000 560000










week 1 - week 2 + week 3 - week 4 + week 5 - week 6 + week 7 - week 8 + week 9 -  Week 10 +
Cell line 1 76 9 179 10.2 245 7.7 215 2.7 171 10
Cell line 2 50 6.3 187 8.6 185 7.8 240 3.2 261 6.2
Cell line 3 125 7.7 161 8.8 210 8.5 201 6.6 142 11.6
Cell line 4 87 8.5 193 6.6 200 10.8 200 7.8 163 9.3
Cell line 5 153 9.6 174 8.8 195 1.8 - - - -
Cell line 6 53 8.3 240 7.4 256 5.4 283 3.9 216 6.6
Cell line 7 45 7.6 133 12.2 220 7.6 172 5.4 212 7
Cell line 8 59 6.7 239 5.2 157 8.9 225 4.6 239 7.4
Cell line 9 47 5.5 218 10.6 196 12.4 265 3.4 156 10.6
Cell line 10 129 9.6 268 6.9 178 11 201 1.1 223 6.4
week 11 - week 12 + week13 - week14 + week 15 - week 16 + week 17- week 18+ Week 19 - Week 20 +
Cell line 1 242 - 77 3.8 65 19.7 - 21.4 53 15.6
Cell line 2 161 - 88 7.3 114 20.8 - 17.7 36 13.3
Cell line 3 213 - 113 4.5 159 19.5 - 10.5 42 10
Cell line 4 185 - 132 4 157 16.2 - 13.6 84 19.2
Cell line 5 - - - - - - - - - -
Cell line 6 256 - 62 10.2 97 17 - 16.1 54 11.7
Cell line 7 205 - 97 7.3 73 16.8 64 8.3 - 9.3
Cell line 8 162 - 112 7.4 118 11.1 114 13.9 - 13.2
Cell line 9 223 - 77 12.6 100 23.2 77 12.1 - 10.2
Cell line 10 171 - 107 8.7 116 17.6 104 17.5 - 10.1
Week 21 - Week 22 + Week 23 - Week 24 + Week 25 - Week 26 + Week 27 - Week 28 + Week 29 - Week 30 +
Cell line 1 81 20.4 101 32.2 100 15.6 75 14.9 83 35
Cell line 2 58 16.8 95 24.5 104 16.9 95 17.2 81 19
Cell line 3 75 17.5 77 14.7 39 14.3 81 12.1 72 13
Cell line 4 85 15.8 100 16.9 81 13.2 52 16.8 87 19
Cell line 5 - - - - - - - - - -
Cell line 6 71 17.3 86 10.2 64 20.7 88 17.2 84 57
Cell line 7 72 16.3 102 16.6 69 16.4 84 18 78 47
Cell line 8 103 11.2 73 10.3 63 8.1 46 5.6 72 43
Cell line 9 71 14.9 76 15 32 17.9 93 17.9 98 23
Cell line 10 58 11 51 18.5 98 11.5 63 16.1 84 27
Week 31 - Week 32 + Week 33 - Week 34 + Week 35 - Week 36 + Week 37 - Week 38 + Week 39 - Week 40 +
Cell line 1 22 50 38 38 25 7 11 24 206 37
Cell line 2 38 40 46 8 33 5 25 73 228 9
Cell line 3 53 54 29 12 3 8 57 52 204 7
Cell line 4 45 34 23 21 8 15 96 64 141 5
Cell line 5 - - - - - - - - - -
Cell line 6 15 53 37 15 14 3 22 59 246 15
Cell line 7 0 47 24 22 58 18 36 21 253 77
Cell line 8 57 35 54 14 18 21 46 77 144 22
Cell line 9 43 24 25 0 18 45 22 119 276 98
Cell line 10 44 27 15 82 39 16 55 104 242 23
Week 41 - Week 42 + Week 43 - Week 44 + Week 45 - Week 46 + Week 47 -
Cell line 1 23 119 16 65 28 16 120
Cell line 2 2 - - - - - -
Cell line 3 - - - - - - -
Cell line 4 - - - - - - -
Cell line 5 - - - - - - -
Cell line 6 1 - - - - - -
Cell line 7 20 44 19 10 7 8 129
Cell line 8 4 2 14 41 46 37 50
Cell line 9 11 105 19 54 11 11 56


























No drug week 1 - week 3 - week 5 - week 7 - week 9 - week 11 - week13 - week 15 -
Mean 82.4 199.2 204.2 200.2 178.3 181.8 86.5 99.9
STDV 39.6462132 41.37578465 29.96961424 77.71000222 73.76547 71.757 36.8457747 46.510333
week 17- Week 19 - Week 21 - Week 23 - Week 25 - Week 27 - Week 29 - Week 31 -
35.9 26.9 67.4 76.1 65 67.7 73.9 31.7
48.24578 30.920867 27.05221 31.17852 33.5029 29.09009 27.02859 21.0082
Week 33 - Week 35 - Week 37 - Week 39 - Week 41 - Week 43 - Week 45 - Week 47 -
29.1 21.6 37 194 6.3 6.8 9.2 35.5
15.53813 17.79638 27.7408644 81.34836 8.680118 8.891944 15.71835445 51.7198651
week 16 + week 18+ Week 20 + Week 22 +Week 24 +Week 26 +Week 28 +
16.19 13.11 11.26 14.12 15.89 13.46 13.58
6.538 5.978749 4.9964877 5.715243 8.607548 5.885047 6.084187
Drug week 2 + week 4 + week 6 + week 8 +  Week 10 +week 12 + week14 +
Mean 7.88 8.53 8.19 3.87 7.51 0 6.58
STDV 1.39028374 2.093402334 3.025612886 2.367863547 3.26818 0 3.61410816
Week 30 +Week 32 +Week 34 +Week 36 +Week 38 + Week 40 +Week 42 +Week 44 +Week 46 +
28.3 36.4 21.2 13.8 59.3 29.3 27 17 7.2




g) Raw data from paclitaxel MTT assay 













Cell lines IC50 IC90
UKF-NB-3 0.567648 0.987432
Cell line 1 0.995 1.47632
Cell line 2 0.84734 1.01233
Cell line 3 0.83691 1.00156
Cell line 4 0.83041 0.99484
Cell line 5 0.85872 1.02407
Cell line 6 0.9116 1.0783
Cell line 7 8.99E-01 1.06505
Cell line 8 0.87068 1.03637
Cell line 9 0.8789 1.04482
Cell line 10 0.88416 1.05021
WEEK 8 
Cell lines IC50 IC90
UKF-NB-3 0.567648 0.987432
Cell line 1 0.62571 1.31984
Cell line 2 0.57333 1.2779
Cell line 3 0.64425 1.27503
Cell line 4 0.72267 1.28903
Cell line 5 - -
Cell line 6 0.54234 0.64584
Cell line 7 5.25E-01 0.62825
Cell line 8 0.82973 0.99414
Cell line 9 0.83073 0.98091
Cell line 10 0.85262 1.01778
WEEK 12 
Cell lines IC50 IC90
UKF-NB-3 0.567648 0.987432
Cell line 1 0.89017 1.08695
Cell line 2 0.88779 1.08451
Cell line 3 0.86619 1.06227
Cell line 4 0.90388 1.10101
Cell line 5 - -
Cell line 6 0.9036 1.10073
Cell line 7 0.90416 1.1013
Cell line 8 0.93799 1.13585
Cell line 9 0.87907 1.07554
Cell line 10 0.89349 1.09036
WEEK 30 
Cell lines IC50 IC90
UKF-NB-3 0.567648 0.987432
Cell line 1 - -
Cell line 2 - -
Cell line 3 - -
Cell line 4 - -
Cell line 5 - -
Cell line 6 - -
Cell line 7 1.06778 5.4323
Cell line 8 0.6332 22.95891
Cell line 9 1.05579 4.70775
Cell line 10 1.24188 4.55892
WEEK 34
Cell lines IC50 IC90
UKF-NB-3 0.567648 0.987432
Cell line 1 0.81803 1.12625
Cell line 2 0.82602 1.13461
Cell line 3 - -
Cell line 4 0.89416 1.2052
Cell line 5 - -
Cell line 6 0.86669 1.1769
Cell line 7 0.85361 1.16336
Cell line 8 1.44336 6.49989
Cell line 9 0.93209 1.24393
Cell line 10 0.90402 1.2153
WEEK 39
Cell lines IC50 IC90
UKF-NB-3 0.567648 0.987432
Cell line 1 0.8574 1.16728
Cell line 2 0.9079 1.21928
Cell line 3 0.99316 1.30552
Cell line 4 1.0653 1.37712
Cell line 5 - -
Cell line 6 1.08094 1.39248
Cell line 7 0.94263 1.25463
Cell line 8 1.24552 10.28793
Cell line 9 0.97133 1.28361
Cell line 10 1.11173 1.42258
WEEK 43
Cell lines IC50 IC90
UKF-NB-3 0.567648 0.987432
Cell line 1 1.02859 1.75516
Cell line 2 - -
Cell line 3 - -
Cell line 4 - -
Cell line 5 - -
Cell line 6 - -
Cell line 7 0.84259 1.1519
Cell line 8 1.9097 8.01299
Cell line 9 0.98778 1.45946
Cell line 10- -
WEEK 45
Cell lines IC50 IC90
UKF-NB-3 0.567648 0.987432
Cell line 1 1.08791 2.17353
Cell line 2 - -
Cell line 3 - -
Cell line 4 - -
Cell line 5 - -
Cell line 6 - -
Cell line 7 0.86105 1.17107
Cell line 8 3.2476 15.53666
Cell line 9 0.89321 1.40653




h) The comparative data of the MTT assay IC50 and IC90 results of all cell lines. The blue bars 






i) Comparison of the IC50 and IC90 data for cell line 8 only.  
 
 
 
 
 
 
 
 
 
